We are pleased to announce that the Center for Antiviral Medicines and Pandemic Preparedness (CAMPP) was selected as one of the National Institute of Allergy and Infectious Diseases (NIAID) Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.

CAMPP has been awarded $67 million for three years, with potential renewal for two additional years. The AViDD Centers' program is one of the U.S. government’s responses to the COVID-19 pandemic and is aimed at the near-term development of drugs against viruses with high pandemic potential — including coronaviruses, filoviruses (such as Ebola virus), flaviviruses (yellow fever virus, dengue virus, Zika virus), paramyxoviruses, bunyaviruses, and togaviruses.

​

Read the press releases from Scripps Research and NIH.

The Center for Antiviral Medicines & Pandemic Preparedness (CAMPP) will draw upon world class drug discovery infrastructure embedded in an academic setting, as well as a network of expert virologists, chemists, pharmacologists, structural and computational biologists, and significant prior investments in global health drug discovery, to generate a more substantial pool of antiviral lead series and candidate drugs with the potential to address the immediate threat of SARS-CoV-2 and provide antiviral drug candidates that might quickly pivot to address future outbreaks or pandemics of other viruses of pandemic concern, including other coronaviruses, flaviviruses, and filoviruses.

Join us on our mission to build better treatments for the current pandemic,

and ensure we are prepared for the next one.

CAMPP is now recruiting for multiple positions!